A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers

Figures

• 

  FIG 1. Disposition of study participants. SAD, single ascending dose; MAD, multiple ascending doses; QD, once daily; BID, twice daily.

• 

  FIG 2. Mean V-7404 plasma concentration-time profiles for single ascending dose. Error bars indicate standard deviation (SD). Mean values BLQ were treated as zero for plotting purposes. The x axis is truncated at the time of the last quantifiable mean. BLQ, below the lower limit of quantification (LLOQ; 1.00 ng/ml); C, cohort.

• 

  FIG 3. Mean V-7404 plasma concentration-time profiles for multiple ascending doses administered once daily (QD), day 1 and day 14. Error bars indicate SD. Mean values BLQ were treated as zero for plotting purposes. The x axis is truncated at the time of the last quantifiable mean. BLQ, below the lower limit of quantification (LLOQ; 1.00 ng/ml); C, cohort.

• 

  FIG 4. Mean V-7404 plasma concentration-time profiles for multiple ascending doses administered twice daily (BID), day 1 and day 14. Error bars indicate SD. Mean values BLQ were treated as zero for plotting purposes. The x axis is truncated at the time of the last quantifiable mean. Three participants were withdrawn before day 14 dosing, so n = 5 for the day 14 pharmacokinetic profile. BID, twice daily; BLQ, below the lower limit of quantification (LLOQ; 1.00 ng/ml); C, cohort.